These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20369750)

  • 1. [Calcimimetic drugs in nondialyzed patients].
    Grzegorzewska AE
    Pol Merkur Lekarski; 2010 Feb; 28(164):170-3. PubMed ID: 20369750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD
    Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical application of calcimimetics].
    Nishi H; Fukagawa M
    Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
    Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
    J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
    Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
    Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
    Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation].
    Vaquero E; Esteban de la Rosa RJ; Oliva N; Fernández Castillo R; Fernández Gallegos R; Bravo Soto J
    Med Clin (Barc); 2012 Apr; 138(8):323-6. PubMed ID: 21492884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cinacalcet in renal transplant patients with hyperparathyroidism.
    Courbebaisse M; Diet C; Timsit MO; Mamzer MF; Thervet E; Noel LH; Legendre C; Friedlander G; Martinez F; Prié D
    Am J Nephrol; 2012; 35(4):341-8. PubMed ID: 22473131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
    Ważna-Jabłońska E; Gałązka Z; Durlik M
    Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
    Grzegorzewska AE; Niepolski L
    Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcimimetics in CKD-results from recent clinical studies.
    Schlieper G; Floege J
    Pediatr Nephrol; 2008 Oct; 23(10):1721-8. PubMed ID: 18594867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
    Goodman WG
    Curr Opin Nephrol Hypertens; 2005 Jul; 14(4):355-60. PubMed ID: 15931004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.
    Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V
    Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.